ECP 2023 Final Programme

Sunday, 10 Sept 28 Scientific Programme a Saturday / Sunday Saturday, 9 Sept e Saturday, 9 September 2023 OC-01 19:00–20:00 The Auditorium Opening Ceremony OC-02 20:00–22:00 The Forum Networking Reception e Sunday, 10 September 2023 SPEC-01 Special Session 08:30–12:00 The Auditorium Trainees Joint Special Session National Societies & Education Subcommittee & Trainees Subcommittee: Setting the stage for the future generations of pathologists Chairs: Xavier Matias-Guiu, Spain Andrzej Marszalek, Poland 001 08:30–08:45 Current residency situation across Europe: input from the ESP Advisory Board Katerina Kamarádová, Czech Republic 002 08:45–09:00 Attracting residents: the Spanish experi- ence Maria Carolina Martinez Ciarpaglini, Spain 003 09:00–09:15 Attracting residents: the German experi- ence Falko Fend, Germany 004 09:15–09:30 Discussion 005 10:30–10:45 Like, post and come to pathology! Alexandra Vilaia, Romania 006 10:45–11:00 ESP tools and supplies to conquer the top Christos Poulios, Belgium 007 11:00–11:15 Paving the way for the future of pathology Marta Cohen, United Kingdom 008 11:15–12:00 Round table discussion, comments and closure of the session LC-01 Long Course 08:30–12:00 Liffey B Breast Pathology Molecular Pathology Joint Long Course: Diagnostic and therapeutic aspects of molecular pathology in breast cancer Chairs: Abeer Shaaban, United Kingdom Sean Hynes, Ireland 001 08:30–08:40 Ancillary molecular testing for breast pathology diagnosis (introduction) Zsuzsanna Varga, Switzerland 002 08:40–09:05 Case presentations of breast entities to illustrate approach to molecular testing Edi Brogi, USA 003 09:05–09:30 Pitfalls in molecular results interpretation: conventional morphology vs. molecular tests? Sunil Lakhani, Australia 004 10:30–11:05 Predictive and molecular testing to guide adjuvant/neoadjuvant therapy in breast cancer – Pathologist perspective Cecily Quinn, Ireland Paul Van Diest, The Netherlands 005 11:05–11:20 Predictive and molecular testing to guide adjuvant/neoadjuvant therapy in breast cancer– Oncologist perspective Janice Walshe, Ireland 006 11:20–11:40 HER2 low – the future Grace Callagy, Ireland 007 11:40–12:00 Molecular testing in the metastatic setting Giuseppe Floris, Belgium